Lv63
1703 积分 2021-08-11 加入
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
1天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
1天前
已完结
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
1天前
已完结
Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial
1天前
求助中
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
1天前
已完结
Pembrolizumab for Early Triple-Negative Breast Cancer
2天前
已完结
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
2天前
已完结
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
2天前
已完结
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
2天前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
6天前
已完结
皖公网安备34019202002308
